Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T17:08:40.077Z.
Calculation as of: 2026-10-06T17:08:40.077Z.
Quote observation: 2026-10-06T17:05:20.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 033b533528001a3499036996a5838431eca9b2abd512acbebbb4929ff412c5bb
PE RATIO
N/A
Market Cap
$772.90M
PE Ratio
N/A
TTM Avg
12.44
3Y Avg
5.97
5Y Avg
5.97
Market Cap
$789.34M
PE Ratio
N/A
TTM Avg
694.69
3Y Avg
438.87
5Y Avg
438.87
Market Cap
$763.75M
PE Ratio
162.48
TTM Avg
129.79
3Y Avg
309.15
5Y Avg
358.87
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | $777.83M | N/A | N/A | N/A | N/A |
| Apnimed, Inc. (APMD)vs › | $781.50M | N/A | N/A | N/A | N/A |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $772.90M | N/A | 12.44 | 5.97 | 5.97 |
| Geron Corporation (GERN)vs › | $789.07M | N/A | 973.22 | 973.22 | 973.22 |
| Gyre Therapeutics, Inc. (GYRE)vs › | $789.34M | N/A | 694.69 | 438.87 | 438.87 |
| Attovia Therapeutics, Inc. (ATTO)vs › | $768.52M | N/A | N/A | N/A | N/A |
| Mesa Laboratories, Inc. (MLAB)vs › | $763.75M | 162.48 | 129.79 | 309.15 | 358.87 |
| AdaptHealth Corp. (AHCO)vs › | $793.88M | N/A | 16.88 | 41.08 | 41.08 |
| Ardelyx, Inc. (ARDX)vs › | $800.37M | N/A | 197.34 | 197.34 | 197.34 |
| Design Therapeutics, Inc. (DSGN)vs › | $750.73M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$2.79
Forward EPS (Est.)
$-0.68
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
